Therapeutic Advances in Endocrinology and Metabolism最新文献

{"title":"Assessing the quality and reliability of health information on GLP-1 receptor agonists on TikTok and Bilibili: a cross-sectional analysis of the public health infodemic.","authors":"Gang Peng, Chen Wang, Hong-Wei Zhang, Ting Xu, Jian-Zhong Di","doi":"10.1177/20420188261467887","DOIUrl":"10.1177/20420188261467887","url":null,"abstract":"<p><strong>Background: </strong>Glucagon-like peptide-1 (GLP-1) receptor agonists have transitioned from clinical tools for diabetes to a global cultural phenomenon for weight loss, triggering an \"infodemic.\" While previous studies have characterized this landscape on Western platforms, the digital health ecosystem in China remains distinct. China is currently navigating a unique market shift driven by the June 2025 approval of the domestic dual agonist mazdutide, an impending 2026 patent cliff for semaglutide, and a specific market for counterfeit products.</p><p><strong>Objectives: </strong>To assess and compare the quality, reliability, and content completeness of health information regarding GLP-1 agonists on China's two dominant video platforms, Douyin (the Chinese version of TikTok) and Bilibili; to examine how platform architecture and regulatory context influence content reliability; and to contrast these findings with recent benchmarks from Western social media studies.</p><p><strong>Design: </strong>Cross-sectional observational study.</p><p><strong>Methods: </strong>A systematic search for \"GLP1\" was conducted on Douyin and Bilibili. Due to divergent algorithms, an asymmetric sampling strategy was used: all 106 videos returned by Douyin were screened, while the top 200 videos from Bilibili's default ranking were assessed. After applying exclusion criteria, 128 videos (56 Douyin, 72 Bilibili) were analyzed. Quality was evaluated using the modified DISCERN tool, Global Quality Score, and JAMA benchmarks. No human subjects were involved; therefore, ethical approval was not required.</p><p><strong>Results: </strong>Bilibili videos were significantly longer and demonstrated superior quality, scoring significantly higher than Douyin videos on both the DISCERN (<i>p</i> < 0.001) and JAMA benchmark (<i>p</i> = 0.003). Unlike findings on TikTok and Instagram, where quality was uniformly low, Bilibili hosted high-quality, in-depth content comparable to patient education materials. However, a safety analysis revealed videos promoting fraudulent products that co-opt the drug's brand name, posing a severe risk unique to the unregulated domestic supply chain.</p><p><strong>Conclusion: </strong>The Chinese digital landscape exhibits a quality tier on Bilibili that is absent in Western short-video counterparts. While Bilibili serves as a reliable \"digital library,\" Douyin remains a high-risk environment for misinformation and counterfeit sales. As China approaches the 2026 patent cliff, regulatory bodies must address the specific threat of fraudulent \"GLP-1\" branding on illicit products.</p><p><strong>Trial registration: </strong>Not applicable.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"17 ","pages":"20420188261467887"},"PeriodicalIF":7.8,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13583291/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148991458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between the ratio of uric acid to high-density lipoprotein cholesterol (UHR) and the abnormal risk of sarcopenia: Evidence from two large population-based surveys and interpretable machine learning-driven sarcopenia screening.","authors":"Yunnong Luo, Aisheng Wang, Minfei Wu, Yang Wang","doi":"10.1177/20420188261489474","DOIUrl":"10.1177/20420188261489474","url":null,"abstract":"<p><strong>Background: </strong>Sarcopenia is a geriatric syndrome linked to nutritional intake, chronic inflammation and metabolic dysregulation. While uric acid (UA) and high-density lipoprotein cholesterol (HDL-C) are recognized biomarkers, their specific relationship with sarcopenia remains debated. The uric acid-to-HDL-C ratio (UHR) has emerged as a novel, integrated biomarker. This study investigates the UHR-sarcopenia association using representative US and South Korean populations and develops an interpretable machine learning screening framework.</p><p><strong>Objectives: </strong>To investigate the association between UHR and sarcopenia in two nationally representative populations and to develop and externally validate an interpretable machine-learning model for sarcopenia screening.</p><p><strong>Design: </strong>A population-based cross-sectional study using NHANES 2011-2018 as the primary cohort and KNHANES 2024 as the external validation cohort.</p><p><strong>Methods: </strong>This cross-sectional study included 7,314 participants from NHANES (2011-2018) and 3,274 from KNHANES (2024). The UHR-sarcopenia relationship was evaluated using multivariable logistic regression, smooth curve fitting, and subgroup analyses. To develop a screening model for prevalent sarcopenia, feature selection was performed using LASSO regression and the Boruta algorithm. Machine learning models were trained on the NHANES cohort, interpreted using SHAP values, and rigorously validated externally using the KNHANES dataset.</p><p><strong>Results: </strong>Higher UHR was significantly associated with greater odds of prevalent sarcopenia. In fully adjusted models, participants in the highest UHR quartile had higher odds of sarcopenia than those in the lowest quartile in NHANES (OR 2.014, 95% CI 1.552-2.625; P<0.001) and KNHANES (OR 1.658, 95% CI 1.183-2.342; P=0.004). Among seven machine-learning models, LightGBM demonstrated the most balanced performance, achieving an AUC of 0.810 in NHANES and maintaining good discrimination during external validation in KNHANES (AUC 0.823).</p><p><strong>Conclusions: </strong>Elevated UHR is significantly associated with sarcopenia. The UHR-integrated LightGBM model demonstrates robust discriminative capacity, serving as a practical and interpretable tool for sarcopenia screening in clinical practice.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"19 ","pages":"20420188261489474"},"PeriodicalIF":7.8,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13569997/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148956406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucose-lowering therapy in diabetes of the exocrine pancreas: a real-world evidence analysis in a tertiary hospital in the timeframe 2018-2022.","authors":"Gea Ciccarelli, Nicoletta Di Giorgi, Chiara Iacomini, Carlotta Masciocchi, Stefano Patarnello, Gianfranco Di Giuseppe, Sara Sofia de Lucia, Enrico Celestino Nista, Antonio Gasbarrini, Alfredo Pontecorvi, Andrea Giaccari, Teresa Mezza","doi":"10.1177/20420188261419207","DOIUrl":"10.1177/20420188261419207","url":null,"abstract":"<p><strong>Background: </strong>Diabetes of the exocrine pancreas (DEP) is a form of diabetes that arises in the presence of an exocrine pancreas disease and is mainly associated with acute and chronic pancreatitis. Therapeutic management of DEP has not changed over the past decades, and treatment is mostly insulin based. However, type 2 diabetes (T2D) treatment guidelines have changed with the aim of normalizing glucose levels and preventing diabetes-related comorbidities.</p><p><strong>Objectives: </strong>The aim of this study was to evaluate real-word practice in the treatment of diabetes associated with pancreatitis, with a focus on individuals who had already developed cardiovascular and/or renal diseases.</p><p><strong>Designs: </strong>We conducted a cross-sectional observational study on adult patients admitted to a tertiary-level hospital in Italy between 2018 and 2022 with a prevalent diagnosis of pancreatitis and diabetes.</p><p><strong>Methods: </strong>Disease-related real-world data were collected from Hospital Information Systems using automated data extraction strategies and through the implementation of a patient-centered data repository. A multiple source real-world evidence-based methodology was used to identify patients with diabetes and to investigate changes in glucose-lowering treatments through hospitalizations.</p><p><strong>Results: </strong>We identified 2146 hospitalized patients with pancreatitis from 2018 to 2022, 675 (31.4%) of whom also had diabetes. Data on glucose-lowering therapies were available for 444 of these patients. Individuals with diabetes and pancreatitis were predominantly male (65.2%) and older than those without diabetes (<i>p</i> < 0.001). At hospital admission, 41.9% were on insulin therapy and 44.4% on other drugs, with metformin being the most prescribed. After hospitalization, insulin use increased significantly (61.2%, <i>p</i> < 0.001) while metformin prescriptions decreased (from 44.7% to 26.2%, <i>p</i> < 0.001). Patients with cardiorenal comorbidities showed similar therapeutic patterns, with a pronounced post-discharge reduction in metformin use.</p><p><strong>Conclusion: </strong>This real-world study provides updated evidence on the treatment of diabetes associated with pancreatitis in a tertiary care setting, showing a predominant use of insulin and metformin regardless of comorbidities. Despite emerging evidence on the benefits of non-insulin therapies in T2D, such approaches are not yet reflected in the management of DEP, underlining the need for specific clinical guidelines and dedicated trials.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"17 ","pages":"20420188261419207"},"PeriodicalIF":7.8,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558923/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148931027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between HOMA-IR and coexisting MASLD and type 2 diabetes: Insights from NHANES and network pharmacology.","authors":"Xian-Pei Heng, Liu-Qing Yang, Qi-Wei Chen, Lin-Xi Jin, Yu-Wan Li, Yi Ruan, Zhuang Han, Shu-Hong Yao, Xin-Miao Hong, Zhi-Ta Wang, Liang Li, Wei-Dong He","doi":"10.1177/20420188261487315","DOIUrl":"10.1177/20420188261487315","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Insulin resistance is a common metabolic feature of metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes (T2D), but its cross-sectional association with the coexistence of these conditions remains incompletely characterized.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objectives: &lt;/strong&gt;To evaluate the associations between the homeostasis model assessment of insulin resistance (HOMA-IR) and the concurrent presence of MASLD and T2D, and to explore potential demographic heterogeneity and generate hypotheses regarding candidate biological pathways.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design: &lt;/strong&gt;Population-based cross-sectional study using data from the National Health and Nutrition Examination Survey 2017-March 2020 pre-pandemic cycle.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Adults with fasting glucose, fasting insulin, vibration-controlled transient elastography, and covariate data were included. Participants were classified as having neither condition, MASLD alone, T2D alone, or both. Multivariable logistic regression evaluated HOMA-IR continuously and by quartiles. Interaction and stratified analyses were conducted by sex and race/ethnicity. Secondary analyses examined concurrent MASLD and prediabetes among participants without T2D. Exploratory mediation analyses used fasting serum insulin as the exposure to assess whether glycemic and lipid indicators statistically accounted for part of the association. Network pharmacology was used as a hypothesis-generating approach to predict candidate targets and enriched pathways.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Among 1,527 participants, each 1-unit increase in HOMA-IR was associated with 59.9% higher odds of concurrent MASLD and T2D versus neither condition (odds ratio [OR] 1.599, 95% confidence interval [CI] 1.491-1.715), 20.2% higher odds versus MASLD alone, and 14.5% higher odds versus T2D alone. When T2D alone was the reference, the association differed by race/ethnicity (P for interaction &lt;0.01). Each 1-unit increase in HOMA-IR was also associated with 22.5% higher odds of concurrent MASLD and prediabetes versus prediabetes alone. Sex-related heterogeneity was observed in secondary comparisons involving concurrent MASLD and prediabetes. The odds of comorbidity were progressively higher across increasing HOMA-IR quartiles (P for trend &lt;0.001). Fasting plasma glucose and hemoglobin A1c statistically accounted for 48.1% and 12.1%, respectively, of the total association between fasting serum insulin and concurrent MASLD and T2D. Hypothesis-generating network pharmacology predicted PRKACA, MAPK1/3, PIK3CA, and SRC as candidate hub targets and suggested candidate pathways related to PI3K-Akt, FOXO, and MAPK signaling.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Higher HOMA-IR was associated with higher odds of concurrent MASLD and T2D. The magnitude of the associations varied by race/ethnicity and the selected reference group, while sex-related heterogeneity was observed in secondary analyses of concurre","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"19 ","pages":"20420188261487315"},"PeriodicalIF":7.8,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13554585/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148920245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between glycerol triglyceride glucose-related index and cardiovascular disease in individuals with metabolic dysfunction-associated steatotic liver disease: NHANES 1999-2023.","authors":"Songshan Li, Shuling Rong, Bin Yang, Huili Cao, Huwei Dai, Yajing Zhao, Bao Li","doi":"10.1177/20420188261487528","DOIUrl":"10.1177/20420188261487528","url":null,"abstract":"<p><strong>Background: </strong>Cardiovascular disease (CVD) is more common in those with metabolic dysfunction-associated steatotic liver disease (MASLD). Although the triglyceride-glucose index (TyG) and its composite indices are straightforward indicators of insulin resistance, it is yet unknown how they relate to the risk of CVD in the MASLD population.</p><p><strong>Objectives: </strong>To explore the correlation of TyG and TyG-waist-to-height ratio (TyG-WHtR) with cardiovascular disease risk in the MASLD population.</p><p><strong>Design: </strong>This was a population-based cross-sectional study using data from the National Health and Nutrition Examination Survey (NHANES) 1999-2023.</p><p><strong>Methods: </strong>Adults with MASLD were included using cross-sectional data from the National Health and Nutrition Examination Survey (NHANES). ROC curve assessments, subgroup analyses, smooth curve fitting, and multivariate logistic regression were carried out.</p><p><strong>Results: </strong>Among 1,860 participants, TyG (OR=1.27) and TyG-WHtR (OR=1.20) were independently associated with elevated CVD risk after full covariate adjustment (all <i>P</i><0.05). TyG exhibited a nonlinear association with CVD risk, with an inflection point at 9.28: below this cutoff, higher TyG was strongly linked to greater CVD risk (OR=2.23, 95% CI: 1.56-3.19), whereas no significant association was detected above the threshold. TyG-WHtR also presented a potential inflection point at 5.54. Stratified analyses revealed stronger associations between both indices and CVD among participants without diabetes, and the magnitude of associations varied across racial subgroups. ROC curve analyses indicated that both markers only achieved modest discriminatory performance for identifying prevalent CVD (AUC: 0.606 for TyG; 0.613 for TyG-WHtR).</p><p><strong>Conclusion: </strong>TyG and TyG-WHtR showed positive associations with CVD in patients with MASLD, with a remarkable threshold effect observed for TyG. Both indices are simple auxiliary markers to screen high-risk subgroups during population epidemiological surveys.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"19 ","pages":"20420188261487528"},"PeriodicalIF":7.8,"publicationDate":"2026-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13554548/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148919985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of vosoritide in children with hypochondroplasia: CANOPY HCH-3 study design.","authors":"Andrew Dauber, Ravi Savarirayan, Ricki Carroll, Moira Cheung, Valérie Cormier-Daire, Mohamad Maghnie, Noriyuki Namba, Oliver Semler, Sajda Ghani, Ian Sabir, Roberto Bassi","doi":"10.1177/20420188261480984","DOIUrl":"10.1177/20420188261480984","url":null,"abstract":"<p><strong>Background: </strong>Hypochondroplasia is a skeletal dysplasia characterized by disproportionate short stature that is caused by gain-of-function variants in the fibroblast growth factor receptor 3 gene (<i>FGFR3</i>), which negatively regulates endochondral bone growth. Current treatments are based on symptom management; there are no treatments targeting the signaling pathways that underlie hypochondroplasia. Vosoritide, a C-type natriuretic peptide analog that counteracts overactive FGFR3 signaling to stimulate endochondral bone growth, is approved for the treatment of achondroplasia in children. A phase 1/2 clinical trial demonstrated that vosoritide treatment for 1 year increased growth in children with hypochondroplasia and was well-tolerated.</p><p><strong>Objectives: </strong>The objectives of CANOPY HCH-3 are to evaluate the efficacy and safety of vosoritide for the treatment of hypochondroplasia in children.</p><p><strong>Design: </strong>CANOPY HCH-3 was a phase 3, randomized, double-blind, placebo-controlled, multicenter study.</p><p><strong>Methods and analysis: </strong>Children aged ≥3 to <18 years with confirmed hypochondroplasia who had ≥6 months of pre-treatment standing height from a prior observational study before randomization were enrolled. Participants were randomized to receive 52 weeks of daily treatment with vosoritide or placebo, followed by 2 weeks of safety follow-up. The primary endpoint is change from baseline in annualized growth velocity at week 52 versus placebo.</p><p><strong>Ethics: </strong>CANOPY HCH-3 was conducted in accordance with the Council for International Organizations of Medical Sciences International Ethical Guidelines, the principles of the Declaration of Helsinki and of Good Clinical Practice, and applicable laws and regulations. Protocols were approved by relevant local health authorities, ethics committees, and institutions. Written informed consent from the participant, or parent or legal guardian, was obtained prior to any study-related procedures being performed.</p><p><strong>Discussion: </strong>CANOPY HCH-3 will provide further evidence for the efficacy and safety of vosoritide in children with hypochondroplasia.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"19 ","pages":"20420188261480984"},"PeriodicalIF":7.8,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13538998/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148888655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Iodine concentrations in human milk after maternal high therapeutic potassium iodide dosing during breastfeeding: a contribution from the ConcePTION project.","authors":"Martje Van Neste, Kaytlin Krutsch, Michael Ceulemans, Heidi Demaegdt, Karlien Cheyns, Nina Nauwelaerts, Pieter Annaert, Anne Smits, Karel Allegaert","doi":"10.1177/20420188261459822","DOIUrl":"10.1177/20420188261459822","url":null,"abstract":"<p><p>Iodine is an essential element of human milk. However, high therapeutic maternal doses of potassium iodide (KI) during breastfeeding and its effect on the infant have been insufficiently studied. Therefore, human milk samples were collected within the UmbrelLACT study to determine human milk iodine concentration (HMIC) and estimate infant exposure during and after high maternal KI intake. One mother used KI 3 × 50 mg/day as preparation for thyroidectomy at 5 months postpartum. Human milk samples were collected opportunistically during and within 2 weeks after KI discontinuation. Furthermore, milk samples were collected over 24-h periods at 3 weeks post-discontinuation and monthly from 1 month up to 5 months after discontinuation of KI intake. Breastfeeding was temporarily interrupted during maternal treatment, with partial resumption of breastfeeding 1 week after KI discontinuation, complemented with infant formula upon the participant's decision. HMIC were analysed using inductively coupled plasma tandem mass spectrometry (ICP-MS/MS) after basic extraction with tetra-methyl ammonium hydroxide (TMAH) and infant exposure was estimated. Median HMIC were 70.8 (46.6-80.8) µg/mL during and 0.064 (0.016-0.227) µg/mL from day six after maternal treatment stop onwards. After discontinuation of KI intake, HMIC decreased quickly and remained within reference range (0.1-0.2 µg/mL). Using the infant requirement of 15 µg/kg/day, relative infant recommended dose (RID_recommended) during and after KI intake was 70805% and 98%, respectively. The infant's thyroid values were within normal ranges at 3 months after discontinuation of maternal treatment and no adverse events were reported for the infant. Post-discontinuation HMIC are in line with mean concentrations in Nordic countries (68-90 ng/mL). High therapeutic doses of KI should not be combined with breastfeeding, but based on these results (exclusive) breastfeeding could be resumed from 3 weeks after finalisation of maternal treatment. Further research is warranted to determine exposure and safety for breastfed infants. <b><i>Registration UmbrelLACT study:</i></b> NCT06042803 (https://clinicaltrials.gov/study/NCT06042803?cond=umbrellact&rank=1).</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"17 ","pages":"20420188261459822"},"PeriodicalIF":7.8,"publicationDate":"2026-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13527343/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148866624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GLP-1 receptor agonists at the crossroads of metabolic and gut inflammation: Implications for people with type 2 diabetes and inflammatory bowel disease.","authors":"Dured Dardari","doi":"10.1177/20420188261478400","DOIUrl":"10.1177/20420188261478400","url":null,"abstract":"<p><p>Obesity and type 2 diabetes now coexist with IBD. Beyond glucose and weight effects, GLP-1 receptor agonists reduce MACE and lower systemic inflammatory biomarkers. Observational IBD data suggest acceptable safety and fewer hospitalisations and surgeries, warranting carefully designed prospective trials.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"19 ","pages":"20420188261478400"},"PeriodicalIF":7.8,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13519219/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148841111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Teplizumab in stage 2 type 1 diabetes- pediatric considerations, realistic expectations, and the evolving technological landscape.","authors":"Hussein Zaitoon","doi":"10.1177/20420188261484779","DOIUrl":"10.1177/20420188261484779","url":null,"abstract":"","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"19 ","pages":"20420188261484779"},"PeriodicalIF":7.8,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13504112/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148819548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unrecognized primary aldosteronism may confound outcomes in adrenal Cushing's syndrome.","authors":"Yongzhang Qin, Shihua Hong","doi":"10.1177/20420188261480541","DOIUrl":"10.1177/20420188261480541","url":null,"abstract":"<p><p>Patients with adrenal Cushing's syndrome may also have undiagnosed primary aldosteronism-a condition that causes high blood pressure and low potassium. Both hormone problems can arise from the same adrenal tumor. In a Colombian registry study of 130 patients, none of the 22 with adrenal Cushing's syndrome were screened for aldosterone excess before surgery. Because high blood pressure and low potassium occur in both conditions, some postoperative problems may be due to unrecognized aldosterone excess rather than cortisol alone. We suggest routine screening for primary aldosteronism in patients with adrenal Cushing's syndrome who have high blood pressure, as recommended by current guidelines, to enable more accurate diagnosis and personalized treatment.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"19 ","pages":"20420188261480541"},"PeriodicalIF":7.8,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13498795/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148798030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}